Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer.

Banerjee R, Russo N, Liu M, Basrur V, Bellile E, Palanisamy N, Scanlon CS, van Tubergen E, Inglehart RC, Metwally T, Mani RS, Yocum A, Nyati MK, Castilho RM, Varambally S, Chinnaiyan AM, D'Silva NJ.

Nat Commun. 2014 Jul 31;5:4527. doi: 10.1038/ncomms5527. Erratum in: Nat Commun. 2016;7:10726.

2.

Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.

Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N.

Oncogene. 2016 Mar 17;35(11):1353-62. doi: 10.1038/onc.2015.212. Epub 2015 Jun 15.

PMID:
26073085
3.

DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?

Pascale RM, Joseph C, Latte G, Evert M, Feo F, Calvisi DF.

DNA Repair (Amst). 2016 Nov;47:12-20. doi: 10.1016/j.dnarep.2016.10.004. Epub 2016 Oct 15. Review.

PMID:
27789167
4.

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.

Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.

5.

Nampt is involved in DNA double-strand break repair.

Zhu B, Deng X, Sun Y, Bai L, Xiahou Z, Cong Y, Xu X.

Chin J Cancer. 2012 Aug;31(8):392-8. doi: 10.5732/cjc.012.10089. Epub 2012 Jun 14.

6.

Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.

Zhao L, Ren Y, Tang H, Wang W, He Q, Sun J, Zhou X, Wang A.

Oncotarget. 2015 Dec 29;6(42):44538-50. doi: 10.18632/oncotarget.6253.

7.

Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.

Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, Lin SC, Li WC.

Oncotarget. 2015 Oct 6;6(30):29268-84. doi: 10.18632/oncotarget.4922.

8.

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.

Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC.

Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552.

9.

Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining.

Jiang W, Crowe JL, Liu X, Nakajima S, Wang Y, Li C, Lee BJ, Dubois RL, Liu C, Yu X, Lan L, Zha S.

Mol Cell. 2015 Apr 2;58(1):172-85. doi: 10.1016/j.molcel.2015.02.024. Epub 2015 Mar 26.

10.

Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells.

Tsuji T, Katsurano M, Ibaragi S, Shima K, Sasaki A, Hu GF.

Biochemistry. 2007 Aug 7;46(31):8920-32. Epub 2007 Jul 14.

PMID:
17630775
11.

Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting.

Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR.

Clin Cancer Res. 2008 Dec 1;14(23):7682-90. doi: 10.1158/1078-0432.CCR-08-1328.

12.

Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining.

Oksenych V, Kumar V, Liu X, Guo C, Schwer B, Zha S, Alt FW.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2234-9. doi: 10.1073/pnas.1222573110. Epub 2013 Jan 23.

13.

Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines.

Nishida Y, Mizutani N, Inoue M, Omori Y, Tamiya-Koizumi K, Takagi A, Kojima T, Suzuki M, Nozawa Y, Minami Y, Ohnishi K, Naoe T, Murate T.

Biochim Biophys Acta. 2014;1839(4):265-74. doi: 10.1016/j.bbagrm.2014.02.004. Epub 2014 Feb 13.

PMID:
24530422
14.

Evidence of an adaptive response targeting DNA nonhomologous end joining and its transmission to bystander cells.

Klammer H, Kadhim M, Iliakis G.

Cancer Res. 2010 Nov 1;70(21):8498-506. doi: 10.1158/0008-5472.CAN-10-1181. Epub 2010 Sep 22.

15.

Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.

Boyko-Fabian M, Niehr F, Distel L, Budach V, Tinhofer I.

PLoS One. 2014 Jun 13;9(6):e98867. doi: 10.1371/journal.pone.0098867. eCollection 2014.

16.

Inhibition of ERK activation enhances the repair of double-stranded breaks via non-homologous end joining by increasing DNA-PKcs activation.

Wei F, Yan J, Tang D, Lin X, He L, Xie Y, Tao L, Wang S.

Biochim Biophys Acta. 2013 Jan;1833(1):90-100. doi: 10.1016/j.bbamcr.2012.10.016. Epub 2012 Oct 23.

17.

AXL mediates resistance to cetuximab therapy.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL.

Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18.

18.

Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.

Nakashima T, Clayman GL.

Arch Otolaryngol Head Neck Surg. 2000 Aug;126(8):957-61.

PMID:
10922227
19.

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.

Yu J, Xie F, Bao X, Chen W, Xu Q.

Mol Cancer. 2014 May 24;13:121. doi: 10.1186/1476-4598-13-121.

20.

DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.

Wu L, Zhang J, Wu H, Han E.

Biochem Biophys Res Commun. 2015 Oct 23;466(3):547-53. doi: 10.1016/j.bbrc.2015.09.068. Epub 2015 Sep 14.

PMID:
26381179

Supplemental Content

Support Center